It may seem counterintuitive, but health officials say that even after you get vaccinated against COVID-19, you still need to practice the usual pandemic precautions, at least for a while. That means steering clear of crowds, continuing to wear a good mask in public, maintaining 6 feet or more of distance from people outside your household and frequently washing your hands. We talked to infectious disease specialists to get a better understanding of why:
Why do I have to continue with precautions after I've been vaccinated?
In the short run, it will take some time for the vaccine's effectiveness to build up. (Effectiveness is defined as not getting sick with COVID-19. If 100 vaccinated people are exposed to a virus, and 50 of them subsequently develop symptoms, that vaccine is 50 percent effective.)
With the Pfizer vaccine, a study published in the New England Journal of Medicine in December found that protection doesn't start until 12 days after the first shot, and reaches 52 percent effectiveness a few weeks later. A week after the second vaccination, the effectiveness rate hits 95 percent. In its application for authorization, Moderna reported a protection rate of 51 percent two weeks after the first immunization, and 94 percent two weeks after the second dose.
"That's not 100 percent," says Paul Offit, director of the Vaccine Education Center and a member of the FDA's vaccine advisory board. "That means one out of every 20 people who get this vaccine could still get moderate to severe infection."
So, reason No. 1 to continue with precautions is to protect yourself.
Can I spread the virus to others even if I'm fully vaccinated?
An important question, but scientists studying the shots' effectiveness don't have an answer yet. And for public health experts, that lack of knowledge means you should act like the answer is yes.
Gain a Better Understanding of Today
MPR News is not just a listener supported source of information, it's a resource where listeners are supported. We take you beyond the headlines to the world we share in Minnesota. Become a sustainer today to fuel MPR News all year long.
Here's why: Before approving the Moderna and Pfizer vaccines, the Food and Drug Administration only asked the vaccine manufacturers whether their products protected people from COVID-19 symptoms. They didn't ask if the vaccines stopped people who'd been vaccinated from nevertheless spreading the virus to others. The emergency authorizations by the Food and Drug Administration that have allowed distribution of the two new vaccines only cite their ability to keep you – the person vaccinated — from getting severely sick from COVID-19.
In the words of the CDC, "Experts need to understand more about the protection that COVID-19 vaccines provide before deciding to change recommendations on steps everyone should take to slow the spread of the virus that causes COVID-19."
The data to answer the question of whether vaccinated people can still spread the virus are just now being collected.
How can you spread a virus if you've been vaccinated?
All the COVID-19 vaccines and vaccine candidates under consideration for use in the U.S. rely on bits of genetic material or virus protein – not anything that could grow into an active SARS-CoV-2 virus.
The concern instead with the COVID-19 vaccine is about whether you might still have an asymptomatic infection despite immunization — without symptoms, but able to shed virus.
Here's how that might work: Let's say you've been vaccinated and you encounter SARS-CoV-2. You're much less likely to develop symptoms – that's clear. But your immune system may not fight off the virus completely – it might allow some viruses to survive and reproduce and get expelled from your nose or mouth in a breath or a cough or a sneeze. Remember: No one can be sure yet if this actually happens, or if it happens often enough that you'd be emitting enough active virus to sicken someone else.
Why didn't the FDA demand information on infectivity before authorizing the first two vaccines?
In a word, time. Larry Corey is a virologist at the Fred Hutchinson Cancer Research Center in Seattle and helps lead the COVID-19 Prevention Network, a federally funded consortium of vaccine experts who've been testing vaccines. "We wanted to get an answer quickly," Corey says, and to do so required as simple an experimental protocol as possible. "You can't hang a lot of bells and whistles on a trial," he says.
Even though the pre-authorization studies of the Pfizer and Moderna vaccines were as streamlined as possible, they still required quite a lot of work. Each of the 75,000 volunteers had to come in to a clinic; get a test for COVID-19; get either a vaccine or placebo shot (without knowing which they'd received); come back for a second shot; and come back to the clinic for testing any time in the interim if they showed any symptoms of having caught the virus.
Adding in even more coronavirus tests along the way to see if the vaccinated volunteers had picked up or were transmitting the virus would have delayed the initial results considerably, Corey says. And in the midst of the pandemic, speed was of the essence.
So how will we get an answer to whether vaccinated people can infect others?
Researchers are checking now on the folks vaccinated in the Pfizer and Moderna trials for antibodies showing that they've been infected. It's not a perfect measure, Corey notes, because the antibody tests aren't always accurate, and antibodies can be transient. Moderna officials have hinted that their vaccine prevents some shedding, but they haven't been specific on how much. Some people who volunteered for the vaccine studies will be checked for evidence of the virus itself.
If someone is found to be shedding virus, then researchers will check to see if that virus is capable of reproducing itself, and if it is, whether there's enough to infect other people. That raises another unknown: It's not yet clear what an infectious dose would be.
Nailing down the answers to all these questions is a laborious process. And no one is saying yet how soon the results of these sorts of studies of the Pfizer or Moderna vaccines will be available.
There are other ways to get at the answer. The COVID-19 Prevention Network has proposed an experimental study that would involve vaccinating more than 20,000 college students with Moderna's vaccine, checking them multiple times per week for virus shedding, and doing contact tracing when infections occurred. The trial, which would cost several hundred million dollars, has so far been turned down by federal funders.
There are other candidate COVID-19 vaccines in the pipeline, and tests will need to be done on them as well. Volunteers in a U.S. experimental trial of the AstraZeneca vaccine tested themselves for the virus. The results so far suggest that candidate vaccine may partly, but not totally, protect against viral shedding. In a commentary published in the same Dec. 8 issue of The Lancet, researchers from Johns Hopkins University say the observation provides some hope that the vaccine stops some asymptomatic shedding, but the evidence gathered so far is too slight to be considered conclusive.
Maybe one of the vaccines that are in the pipeline would be a better idea?
If your turn for vaccination comes, there's no reason to wait – while vaccines currently being tested are different in design from the Pfizer and Moderna products, scientists say there's no biological reason to think those vaccines will be more or less protective against shedding.
Now that I'm vaccinated, can I take my mask off in a crowded room if everyone else has also been vaccinated?
You might think you're home free in that case, but not yet. Remember the Pfizer and Moderna vaccines are not 100 percent effective, and many in the research community still advise caution. Once most people are protected and there's less virus circulating in the air — and less circulating in the community — the advice and restrictions on this may ease up a bit. One vision of the new normal — whether that's later in 2021 or even 2022 — is an eventual relaxation of the recommendations, with occasional renewals when the virus flares up in a community.
What about the new variant from the U.K. – will that make a difference in terms of spreading the virus after vaccination?
The newly identified variant — B.1.1.7 — hasn't been around long enough to say for certain that the new vaccines are effective against it, but scientists aren't too worried about that – lab studies suggest they will be protective against this strain.
However, infectious disease specialists are concerned that any strain that is more contagious — which B.1.1.7 clearly is — might quickly increase the number of COVID-19 cases in the world.
"It appears that the people infected with this new variant at least in the U.K., have an increased amount of virus," says Dr. David Heymann of the London School of Hygiene and Tropical Medicine. "The hypothesis is they could spread it more easily from their nasal passages. Whether there is actually an increased risk of transmitting the virus is currently being studied."
If the new variant increases the risk of shedding, or just provides more chances for it to happen – increased masking and distancing, crowd avoidance and handwashing will help stop the spread.
So what's the bottom line?
With cases and deaths surging throughout the U.S., the people who are treating COVID-19 patients really want you to continue to wear a mask, keep your distance and wash your hands, even if you've been vaccinated, until the research on shedding has yielded some answers. Dr. Carlos del Rio of Emory University says he knows taking precautions can be taxing, but he urges us all to hang on, and keep it up.
"It's not like you'll need to wear a mask for the rest of your life," he says. "You need to wear your mask until we have the data, and we're trying to get the answers as fast as we can."
Joanne Silberner, a former health policy correspondent for NPR, is a freelance journalist living in Seattle.
Copyright 2021 NPR. To see more, visit https://www.npr.org.